Navigation Links
Genzyme Reports Strong First-Quarter Growth
Date:4/23/2008

ress in advancing programs within its late-stage development pipeline. These programs have significant potential to drive the company's growth beyond 2011.

Mozobil(TM) (plerixafor) for stem-cell transplantation

-- Genzyme plans to file mid year for U.S. and European approval for

Mozobil's use in treating patients with multiple myeloma and patients

with lymphoma. The company expects to launch the product in the United

States early next year upon approval and to rapidly expand the

product's availability around the world. The company anticipates peak

annual sales of the product in the transplant setting of $400 million.

Mozobil is an innovative product intended to enhance the mobilization

of stem cells for transplantation in patients with lymphoma and

multiple myeloma. In two pivotal clinical studies, Mozobil showed the

ability to quickly and predictably prepare cancer patients for a

transplant to treat their disease. Genzyme is also exploring

additional indications for Mozobil, including its potential use in

chemosensitization procedures.

Clolar for adult AML

-- Clolar is approved in the United States and Europe for the treatment of

acute lymphoblastic leukemia in relapsed and refractory pediatric

patients. Genzyme is developing the product for use globally as a

first-line therapy for the treatment of adult acute myeloid leukemia

(AML) and myelodysplastic syndromes, significantly larger indications

that the company estimates will drive peak annual sales of the product

to approximately $600 million. The company intends to submit a

supplemental new drug application in the United States later this year

to include an adult AML indication. This application will be based on

results from the CLASSIC II clinical trial involving older adult AML

<
'/>"/>
SOURCE Genzyme Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Genzyme to Build New R&D Center in Beijing
2. Genzyme Provides Update on Myozyme(R) Manufacturing
3. Genzyme Withdraws Bioenvisions European Filing of Evoltra(R) in Elderly AML Patients
4. Genzyme Launches Renvela(R) in the U.S. for Dialysis Patients
5. Genzyme and Isis Announce Hart-Scott-Rodino Approval of Collaboration
6. Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
7. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
8. Genzyme Receives European CE Mark for Single-Treatment Synvisc-One(TM)
9. Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation
10. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
11. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... Texas (PRWEB) November 26, 2014 ... Industry is an in-depth research report on the ... the report introduces Palmitic Acid, basic information, including ... policy analysis, and news analysis, etc. , ... analyzes Palmitic Acid market in China ...
(Date:11/26/2014)... TOKYO , 25 novembre 2014 /PRNewswrie/ -- Theravalues ... per il mercato europeo in occasione di Hi Europe ... ). Si tratta della curcumina con ... tecnologia amorfa (senza cristalli) e ingredienti approvati dalle norme ... presente nella spezia della pianta curcumina ( Curcuma longa ...
(Date:11/24/2014)... , UAE, November 24, 2014 ... "Sheikh Hamdan Bin Rashid Al Maktoum Awards for Medical ... Dubai, United Arab Emirates , on ... ) , The Carter Center which ... Services is actively involved in numerous programs that aim ...
(Date:11/24/2014)...   First published ... Elsevier , a world-leading provider of scientific, technical ... the launch of the latest title in the Current ... Food Science . Current ... new platform to keep up-to-date with the expanding volume of ...
Breaking Biology Technology:Palmitic Acid Industry Global 2014 Analysis & 2020 Forecasts on Market data, Statics, Development Now at ReportsnReports.com 2Palmitic Acid Industry Global 2014 Analysis & 2020 Forecasts on Market data, Statics, Development Now at ReportsnReports.com 3La curcumina con la maggiore biodisponibilità di sempre farà il suo debutto in Europa 2La curcumina con la maggiore biodisponibilità di sempre farà il suo debutto in Europa 3Five US Winners Among Recipients of Hamdan Medical Awards 2Elsevier Announces Launch of New Journal: Current Opinion in Food Science 2Elsevier Announces Launch of New Journal: Current Opinion in Food Science 3
... VAP Cholesterol test can help doctors and clinicians identify ... options for patients at risk of heart disease, ... a,new cholesterol-fighting drug combination point to the need for ... other,lipids. That,s according to Atherotech, a cardio-diagnostic company that,has ...
... ABAX ), a medical products company manufacturing point-of-care,blood ... its,financial results for the third quarter of fiscal year ... 4:15 p.m. ET, Thursday, January 31, 2008., Participants ... the,conference call, or can listen via a live Internet ...
... ARIUS, Product Candidate Trop-2 Signal ... Transduction Antibody ... a full-,service biopharmaceutical development and protein production company, today,announced that ... Research, Inc., a biotechnology company focused on discovering,and developing the ...
Cached Biology Technology:Atherotech Says Detailed Cholesterol Test Can Help Doctors and Patients Choose Best Therapy 2Atherotech Says Detailed Cholesterol Test Can Help Doctors and Patients Choose Best Therapy 3Abaxis to Report Third Quarter Fiscal 2008 Financial Results Thursday, January 31, 2008 2Laureate Announces Manufacturing Agreement with ARIUS for Trop-2 Targeting Antibody 2Laureate Announces Manufacturing Agreement with ARIUS for Trop-2 Targeting Antibody 3
(Date:11/15/2014)... -- While we may still be a few years away from ... to gain instant access to all that ailed his patients, ... tablets for monitoring and measuring our health are cropping up ... a tad Orwellian to some, but a new survey suggests ... opportunities into their healthcare regime. These are some ...
(Date:11/10/2014)... appearing on U.S. store shelves in early 2010, and ... The small packets can be tossed into a washing ... or powder. The convenience, though, has come with risks ... at Nationwide Children,s Hospital found that from 2012 through ... children younger than 6 years of age swallowing, inhaling, ...
(Date:11/7/2014)... , November 6, 2014 Leading ... for better mobile security revolutionizing online transactions.  Companies in focus ... Holdings Ltd. (NYSE: BABA ), Google Inc. (NASDAQ: ... ), eBay Inc. (NASDAQ: EBAY ) and MasterCard ... NXTD and NXTDW), a biometric authentication company focused on ...
Breaking Biology News(10 mins):Americans May Be Ready for a Brave New World of Healthcare 2Americans May Be Ready for a Brave New World of Healthcare 3Americans May Be Ready for a Brave New World of Healthcare 4Study finds laundry detergent pods, serious poisoning risk for children 2Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 2Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 3Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 4Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 5Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 6
... 2010 Fido,s wet licks might hold more than love. ... for rare cancers and other diseases in both dogs and ... the Van Andel Research Institute (VARI) have created the Canine ... cancers in dogs to better understand why both pets and ...
... Abstract:, The transfer of scientific data has emerged as ... size and demand as open access sharing increases. Current ... large files and can cause long transfer times. In ... open access sharing of scientific data and uses the ...
... different environments don,t necessarily also have different ecological ... investigating the accuracy of current statistical tests that ... in environmental requirements. In a new study ... a model simulating the distributions of two imaginary ...
Cached Biology News:Slobbery kisses from 'man's best friend' aid cancer research 2Slobbery kisses from 'man's best friend' aid cancer research 3Slobbery kisses from 'man's best friend' aid cancer research 4Slobbery kisses from 'man's best friend' aid cancer research 5BioTorrents: An OA file sharing service and more 2BioTorrents: An OA file sharing service and more 3BioTorrents: An OA file sharing service and more 4BioTorrents: An OA file sharing service and more 5Species distribution models can exaggerate differences in environmental requirements 2
12 breakable polypropylene strips of 8 wells each held in a rigid frame. Ideal for antibody assays....
... A direct, simple approach ... the well surface of an ... anhydride maintains its integrity and ... under dry, room temperature conditions ...
... Stabilizer is a bovine protein-free alternative to ... aqueous solution that contains non-toxic chemicals in ... 6.6 - 7.2, and does not contain ... activity of antibodies and other biomolecules that ...
... This coating stabilizer is designed ... as antigens and antibodies for immunoassay ... coating molecules during the coating and ... storage. It can also works ...
Biology Products: